Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 4Carcinoma 4Stomach Neoplasms 3Peritoneal Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 3Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1Ascites 1Adenocarcinoma 1

Interventions

Bevacizumab 5pembrolizumab 4Gemcitabine 4Cisplatin 4napabucasin 3Paclitaxel 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3lenvatinib 2entinostat 2anlotinib 2Taxes 2Sunitinib 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Leucovorin 2Immunotherapy 2Fluorouracil 2Carboplatin 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1olaparib 1niraparib 1luprolide acetate gel depot 1linifanib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × catumaxomab × Clear all
NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed
32 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡